Podcasts about pharmacogenetics

In this episode, you'll hear about the latest developments in tailoring cancer treatments to individual patients using Precision Oncology.  Two thought leaders, Simone Ndujiuba, a Clinical Oncology Pharmacist at Prime Therapeutics, and Karan Cushman, Head of Brand Experience and host of The Precision Medicine Podcast for Trapelo Health, discuss real-world research that is paving the way for Prime and our partners to help providers reduce turnaround times so patients can start treatment as soon as possible.  Join your host Maryam Tabatabai as they dig into this evolving topic of precision oncology. www.primetherapeuitics.com ⁠Chapters⁠Defining precision medicine (08:50)Evaluating real-world operational process of biomarker testing (14:36)Turnaround times are crucial (17:40)A patients view into the importance of time (24:39)Technology and process aid in time and process (29:30)Helping bridge knowledge gaps for providers and payers (33:55) The focus is on Precision Oncology right now (37:00)Precision medicine in other disease categories (40:09)Future of precision oncology is bright (42:07) References Singh, B.P., et al. (2019). Molecular profiling (MP) for malignancies: Knowledge gaps and variable practice patterns among United States oncologists (Onc). American Society of Clinical Oncology. https://meetings. asco.org/abstracts-presentations/173392 Evangelist, M.C., et al. (2023). Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study. Journal of Clinical Oncology, 41(Supplement 16). https://doi.org/10.1200/JCO.2023.41.16_suppl.9109. Ossowski, S., et al. (2022). Improving time to molecular testing results in patients with newly diagnosed, metastatic non-small cell lung cancer. Journal of Clinical Oncology, 18(11). https://doi.org/10.1200/OP.22.00260 Naithani N, Atal AT, Tilak TVSVGK, et al. Precision medicine: Uses and challenges. Med J Armed Forces India. 2021 Jul;77(3):258-265. doi: 10.1016/j.mjafi.2021.06.020.  Jørgensen JT. Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy. Oncologist. 2019 Jul;24(7):e432-e440. doi: 10.1634/theoncologist.2019-0054.  MedlinePlus. What is genetic testing? Retrieved on April 21, 2025 from https://medlineplus.gov/genetics/understanding/testing/genetictesting/. MedlinePlus. What is pharmacogenetic testing? Retrieved on April 21, 2025 from https://medlineplus.gov/lab-tests/pharmacogenetic-tests/#:~:text=Pharmacogenetics%20(also%20called%20pharmacogenomics)%20is,your%20height%20and%20eye%20color.  Riely GJ, Wood DE, Aisner DL, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines: non-small cell lung cancer, V3.2005. Retrieved April 21, 2025 from https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.  Benson AB, Venook AP, Adam M, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines: colon cancer, V3.2025. Retrieved April 21, 2025 from https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Rosenberg PS, Miranda-Filho A. Cancer Incidence Trends in Successive Social Generations in the US. JAMA Netw Open. 2024 Jun 3;7(6):e2415731. doi: 10.1001/jamanetworkopen.2024.15731. PMID: 38857048; PMCID: PMC11165384. Smeltzer MP, Wynes MW, Lantuejoul S, et al. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol. 2020 Sep;15(9):1434-1448. doi: 10.1016/j.jtho.2020.05.002.The views and opinions expressed by the guest featured on this podcast are their own and do not necessarily reflect the official policy or position of Prime Therapeutics LLC, its hosts, or its affiliates. The guest's appearance on this podcast does not imply an endorsement of their views, products, or services by Prime Therapeutics LLC. All content provided is for informational purposes only and should not be construed as professional advice.

Could ketamine be the key to unlocking a new era of ADHD treatment…This week, we're diving deep with the brilliant Dr. Wayne Kampers, a seasoned integrative consultant psychiatrist with over 35 years of experience. We explore the fascinating world of ketamine therapy and its potential in treating complex conditions, especially those intertwined with trauma.We dive into:✨ What exactly is ketamine therapy and how it differs from its recreational use

Did you know you can specialize when you work in primary care? As a surgical PA, I've worked in various surgical subspecialities, but the concept of primary care subspecialities was brand new to me. My guest today, Alex Childs, shares his story of specializing in pharmacogenetics as a primary care PA.  Alex is a PA with a Doctor of Medical Science degree working in family medicine in Utah. Alex's doctorate research focused on implementing genetic testing in primary care. In practice, he has done this with hereditary cancer risk testing and pharmacogenetic testing. In today's episode, Alex shares what he loves about working in primary care and gives actionable tips on how to thrive as a primary care provider. Alex also explained what the heck pharmacogenetics is and how he uses it to provide high quality care and early interventions with his patients. He also describes how he began working as an medical science liaison (MSL) in industry while still working as a family medicine PA. I think my favorite part of our discussion was talking about how every medical provider can get their joy back when it comes to practicing medicine. Press play to learn how to find your passion for medicine again if you've been feeling burned out. SPONSORSAAPA Job Source: aapa.org/pajobsourceFreed AI [DISCOUNT CODE: PA50] https://www.getfreed.aiREFERENCES1. Fred HL, Scheid MS. Physician burnout: causes, consequences, and (?) cures. Tex Heart Inst J. 2018;45(4):198-202. doi:10.14503/THIJ-18-68422. Samuel D. Who Are Medical Science Liaisons? THE MSL. March 27, 2020. Accessed February 3, 2025. https://themsljournal.com/article/who-are-medical-science-liaisons/3. Carrau D, Janis JE. Physician burnout: solutions for individuals and organizations. Plast Reconstr Surg Glob Open. 2021;9(2):e3418. doi:10.1097/GOX.0000000000003418CONNECT WITH ALEXLinkedIn: https://www.linkedin.com/in/alex-childs-565b4884COACHING⁠1-ON-1 NEGOTIATION CONSULT https://calendly.com/the-pa-is-in/negotiate⁠ ⁠FREE 30-MINUTE COACHING CONSULT⁠ ⁠https://calendly.com/the-pa-is-in/gen-call⁠  LINKS⁠TRACY ON INSTAGRAM https://www.instagram.com/mrstracybingaman/⁠⁠TRACY ON LINKEDIN https://www.linkedin.com/in/tracybingaman/⁠SUPPORT THIS PODCAST: https://podcasters.spotify.com/pod/show/thepaisin/supportKeywords: Pharmacogenetic testing, Hereditary cancer risk testing, PA career growth, Primary care subspecialties, Doctor of Medical Science PA, Physician assistant career paths, PA industry jobs, PA professional development, Genetic testing in medicine, How to thrive as a primary care PA. Secondary keywords: Pharmacogenetic testing, Hereditary cancer risk testing, PA career growth, Primary care subspecialties, Doctor of Medical Science PA, Physician assistant career paths, PA industry jobs, PA professional development, Genetic testing in medicine, How to thrive as a primary care PALong-tail keywords: Can physician associates specialize in primary care?, How to implement genetic testing in primary care, Pharmacogenetics for primary care providers, What is a medical science liaison (MSL) in healthcare?, Career options for physician associates outside clinical practice, How PAs can work in both industry and clinical practice, Overcoming burnout as a primary care provider

We here at NAVAS are excited to bring you a new podcast episode for the new year! And we're starting out our season of the NAVAS podcast with engaging exploration of pharmacogenetics, a groundbreaking field that examines how the genetic makeup of an animal can influence its response to medications. Have you ever had a dog or a cat that took hours, if not days, to finally return to normal after general anesthesia? It's possible that animal had a genetic mutation that altered its metabolic function, causing profound changes in the clinical effects of anesthetic drugs. In this episode, we are joined by veterinary anesthesiologist and overall gene-ius Dr. Tania Perez Jimenez, Assistant Professor of Anesthesia at Washington State University College of Veterinary Medication and head its Pharmacogenetics Laboratory. Dr. Perez Jimenez shares her expertise on the genetic factors that impact anesthesia and pain management in dogs and cats. Together with host, Dr. Bonnie Gatson, they will discuss how genetic variations can affect drug efficacy and safety in individual animals, how you can approach anesthetic management in dog breeds that commonly manifest genetic anomalies such as MDR1 mutations, why we may need to alter the way we utilize Propofol and Alfaxalone in cats and certain dog breeds, and how we could all benefit from going to more cat shows.Explore more information discussed on this podcast at the WSU Pharmacogenetics Laboratory website.If you like what you hear, we have a couple of favors to ask of you:Become a member of NAVAS for access to more anesthesia and analgesia educational and RACE-approved CE content.Spread the word. Share our podcast on your socials or a discussion forum. That would really help us achieve our mission: Reduce mortality and morbidity in veterinary patients undergoing sedation, anesthesia, and analgesia through high-quality, peer-reviewed education.Thank you to our sponsor, Dechra - learn more about the pharmaceutical products Dechra has to offer veterinary professionals, such as Zenalpha.If you have questions about this episode or want to suggest topics for future episodes, reach out to the producers at education@mynavas.org.All opinions stated by the host and their guests are theirs alone and do not represent the thoughts or opinions of any corporation, university, or other business or governmental entity.

DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.       Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. Welcome back to "Ditch the Lab Coat," the podcast where we explore the fascinating world of health and medicine with a skeptical eye. I'm Dr. Mark Bonta and In today's episode, Dr. Kaplovitch dives deep into the different types of blood clots and the importance of personalized treatment. He explains that not all blood clots are created equal - some predominantly affect the veins, while others can travel to the lungs and become life-threatening. We discuss the various risk factors that can lead to blood clot formation, from genetic conditions to long plane rides, and Dr. Kaplovitch offers practical advice on managing this complex disorder.We also touch on the fascinating history behind some blood thinning medications, like warfarin, which was originally used as rat poison! Dr. Kaplovitch clarifies the distinctions between its toxic properties and medical use. Throughout our conversation, we emphasize the importance of transparently counseling patients about the risks and benefits of different treatments. Dr. Kaplovitch highlights the abundance of research in the field of thrombosis and how it informs the personalized approach he takes with his patients.So join us as we simplify these complex medical concepts and explore the latest advancements in blood clot prevention and treatment. As always, remember that this podcast is for informational purposes only and does not substitute for professional medical advice. Let's ditch the lab coat and dive in!04:24 Experienced medical student impresses with professionalism.09:02 Blood clots can travel to lungs, fatal.12:14 Prolonged sitting at desk may increase thrombosis risk.16:01 Minority with blood clots can improve naturally.18:45 Clot busters have significant risk of bleeding.20:59 Treatment options for preventing blood clot complications.25:39 Passion for vascular medicine, citing primary literature.29:26 Newer blood thinners may have advantages.31:37 Warfarin inhibits clotting by blocking vitamin K.36:09 Balancing blood thinness for health benefits is crucial.37:22 Maintain optimal blood thinness to prevent risks.42:22 Minor bleeding from gut might not require action.46:27 Consistent blood thinner use is crucial.50:05 Discussing evolving thrombosis practices, specifically genetic testing controversies.51:24 Testing for clotting disorders requires informed discussion.57:02 Advancements in personalized medicine revolutionize treatment.58:45 Hip hop slang reference and deep thrombosis.

Scholarly analytics, Weight-bias reduction, NP fellowships, Pharmacogenetics, Late preterm infant care, Foot care in patients with Diabetes, Internalized stigma of mental illness, NP and PA leadership structure in an academic cancer center.

Join us in this enlightening episode as we delve into the intersection of pharmacogenetics and pregnancy with our esteemed guest, Dr. Ina Liko. With residency and fellowship training in pharmacogenomics along with years of experience in clinical experience ranging from patient-specific to systemwide applications, Dr. Liko, the Director of Clinical Pharmacogenomics Operations at RxGenomix, is at the forefront of innovation in improving patient outcomes. We explore the vital role pharmacogenetic information plays in enhancing pregnancy outcomes. From preconception to postpartum care, Dr. Liko guides us through the clinical applications of pharmacogenomics, touching upon various medication classes and their impact on maternal health. Whether it's optimizing IVF protocols, managing hyperemesis, addressing pain management, or tackling postpartum depression, we uncover how tailored medication strategies can significantly improve maternal and fetal well-being. Dr. Liko sheds light on the intricacies of interpreting genetic test results to determine appropriate medication doses, empowering both patients and providers with actionable insights. We also discuss overcoming barriers in implementing pharmacogenetic testing within healthcare systems, highlighting the evolving landscape and the importance of pharmacist involvement in precision medicine in pregnancy. To dive deeper into this topic, visit Dr. Liko's PGx Clinical Pearls at https://rxgenomix.com/insights-news/clinical-pearls/.  Connect with Dr. Plummer at https://www.linkedin.com/in/daniellerplummer/

The LTC pharmacy industry is a growing subsect of the industry. And within that niche are other niches on the rise. That's where Rob Leffler comes in. A consultant pharmacist with two decades' worth of experience, the Vice President of Clinical Services for Synchrony Pharmacy knows the inner workings of LTC facilities along with their soaring potential. Join host Frances Nahas and Rob as they discuss all things LTC from what being a consultant pharmacist looks like to pharmacogenetics and his upcoming class at AmplifyLTC.  Hosted By: Frances Nahas, Chief Strategy Officer of RedSail Technologies  Guest: Rob Leffler | Vice President of Clinical Services, Synchrony Pharmacy Looking for more information about independent pharmacy? Visit https://www.redsailtechnologies.com/next-wave/amplifyltc

We have recently been asked the question, "Are all AAS equal on a mg/mg basis?" Today, Dr Scott Stevenson explores this topic in this lecture. With Scott McNally TIME STAMPS BELOW - Muscle Minds Podcast 156 0:00 Teaser 0:45 Intro 1:30 Are All Steroids Equally Anabolic? 2:30 What is the question exactly? 6:20 Why ask the question? 12:20 Is it likely that all AAS are equal on a mg/mg basis 25:20 Pharmacogenetics and Pharmacodynamics 31:40 AAS Data in Humans 41:30 Supra physiological Test Study 43:50 Deca Study 51:45 Study comparison of multiple AAS 1:05:20 What can we make of this? 1:07:30 Practical dose response curves 1:15:00 Concluding Thoughts on AAS Anabolic Equivalency 1:19:00 Amazing Dog Pics!!

This episode is a collaboration between the ACCP Ambulatory Care Practice and Research Network (PRN) ... and iForumRx.org. Mental illness is very common - 1 in 5 adults in the United States will have a mental illness during their lifetime.  Every ambulatory care (and community) pharmacist should be confident in their ability to recognize mental health challenges and how to use medications in an optimal manner to treat them.  This is a FOLLOW-UP conversation from the ACCP Annual Meeting program entitled Ambulatory Care PRN Focus Session — Breaking Down Depression and Anxiety Management for the Ambulatory Care Pharmacist. Expert Panelists:  Richard Silvia, PharmD, BCPP and Jordan Baye, PharmD, BCPS Music by lemonmusicstudio from Pixabay

There's no doubt new advances in science and technology are having a huge impact on the way we live our lives these days. From Big Data and artificial intelligence to genomics and wearable devices that track daily our activity. Of course, medicine is no exception. All of these technological steps forward are pointing healthcare towards a coming era of personalised medicine that focusses more directly on the needs of the individual patient. In this episode we speak to Professor Sir Munir Pirmohamed, David Weatherall Chair in Medicine at the University of Liverpool, NHS Chair of Pharmacogenetics, and a consultant physician at the Royal Liverpool University Hospital. He tells us how advances in medical techniques such as genetic screening and a focus on patients' differing reactions to treatment can go beyond a one-drug-fits-all approach to healthcare and even treat diseases before symptoms appear. Learn more about your ad choices. Visit podcastchoices.com/adchoices

https://swiy.co/WhatAreYourThoughtsDiscover some eye-opening exploration of genetics, medication choices, and evidence-based practices in pediatric psychiatry! Join host Dr. Lia Gaggino and guest Dr. Lisa Namerow as they navigate the intricate world of pharmacogenomic testing, the impact on prescribing behavior, and the crucial relevance of genetic panels for pediatric patients. From the evolving landscape of pharmacogenomics to the challenges of interpreting genetic findings, this discussion sheds light on the pivotal role of nonpharmacologic options and the need for validated guidelines in treating pediatric anxiety and depression. The conversation between Dr. Gaggino and Dr. Namerow has shed light on the challenges and opportunities associated with pharmacogenomic testing in pediatric psychiatry. With the complexity of interpreting results and the risk of inappropriate medication choices, the field faces a critical juncture in the responsible adoption and implementation of genetic information. However, the lack of clear guidelines and the risk of misinterpretation highlight the need for caution in prescribing decisions. As we navigate this landscape, it is essential for providers to prioritize the validation of guidelines and the responsible use of genetic information to ensure the safe and effective treatment of pediatric anxiety and depression. Together, we can work towards a future where genetic testing enhances the care of pediatric patients facing mental health challenges. [00:33 -12:41] The Conundrum of Genetics in PsychiatryGenetics play a complex role in determining the right treatment for psychiatric conditions.Non-specialists may struggle to fully comprehend the intricacies of genetic information.The science of genetics in mental health treatment is fast evolving.Genetic information can significantly alter clinical decisions in unexpected ways.[12:42 - 28:33] Understanding Clinical Pharmacogenetics Learn what pharmacogenetics is and how it impacts drug efficacy and patient safety.Identify common drugs with known pharmacogenetic interactions.Understand the importance of integrating pharmacogenetic information into clinical practice.Stay updated on emerging research and its implications for personalized medicine.[28:34 - 33:05] Moving Beyond the Binning Concept in Data AnalysisEmbrace new frameworks for interpreting genetic testing results.Develop a nuanced understanding free from oversimplified categories.Foster continuous learning and adaptation in data evaluation methods.Integrate complex data sets for a more personalized approach to healthcare.[33:06 - 44:13] Utilizing Sequence to Script in Clinical Practice Streamline patient information intake by inputting data into Sequence to Script.Enhance patient interactions by leveraging generated scripts for more effective communication.Document clinical reasoning meticulously when selecting treatment options based on script suggestions.Improve the accuracy of allergy identification and management with advanced Sequence to Script outputs. [44:14 - 51:44] Closing segment TakeawayLinks to resources mentioned on the showSequence 2 Script: www.sequence2script.orgPharmacogenomics: An Update for Child and Adolescent Psychiatry

In this episode of HR Benecast, we're joined by Travis Baughn, vice president of clinical solutions at Optum Rx. Listen to hear how pharmacogenetics works and its importance for employers. He'll share what plan participants need to know, and how it can be used to reduce medical waste and long and complex medication journeys.  For additional resources on pharmacogenomics, please visit cpicpgx.org and pharmgkb.org. 

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the November 2023 issue of DTB. They discuss the history of the BNF and the announcement that the 86th edition of the BNF and the 2023–2024 edition of the BNF for Children will be the last print issues to be purchased by the National Institute for Health and Care Excellence for the NHS in England (https://dtb.bmj.com/content/61/11/162 and https://dtb.bmj.com/content/61/11/166). They talk about a retrospective review of a case series of UK coroners' Reports to Prevent Future Deaths that found that around one in five reports involved a medicine (https://dtb.bmj.com/content/61/11/165). The main article provides an introduction to pharmacogenetics (https://dtb.bmj.com/content/61/11/168). They begin by responding to a listener's email.   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

Pharmacogenetics: Personalized Medicine for the Future In a this episode of the podcast "Self Funded" hosted by Spencer Smith, entrepreneur Nick Glimcher shared his journey from the world of commercial real estate to the healthcare industry. Glimcher's story highlights the importance of adaptability and seizing opportunities in different industries. He emphasizes the link between powerlifting and entrepreneurship, both requiring consistent effort and commitment for success. One of the key challenges in the healthcare industry, as discussed in the episode, is the complex landscape of insurance companies and payment issues. These challenges can be daunting and hinder the delivery of quality care. However, Glimcher believes that precision medicine holds the key to overcoming these challenges and revolutionizing healthcare. Precision medicine is an innovative approach that provides detailed and targeted care based on an individual's genetic makeup. Glimcher explains that precision medicine is the future of healthcare, with pharmacogenetics playing a crucial role in personalizing treatment plans. Pharmacogenetics is the science of determining which drugs work for an individual and which do not. While the science has been commercially viable since 2010, its widespread usage has been limited due to applicability issues. To address this issue, Glimcher's company, Blue Genes, has developed a software tool called The Blue Genes Solution. This tool aims to make pharmacogenetic data actionable in clinical settings. By integrating with pharmacy benefit managers (PBMs) and electronic medical records (EMRs), Blue Genes simplifies the interpretation of pharmacogenetic reports and provides instantaneous notifications to healthcare providers, ensuring that prescriptions are genetically efficacious. Cost mitigation in healthcare is a pressing issue that requires innovative solutions, such as precision medicine, and bipartisan support. Glimcher highlights the importance of government involvement in pushing for coverage determinations and legislation related to pharmacogenetics. He believes that there is bipartisan support for healthcare reform because humanity and caring are not political issues but fundamental aspects of being human. The episode also touches on the challenges faced by healthcare providers in adopting technology. Healthcare has been the last sector to embrace technological advancements, despite its critical role in keeping people alive and healthy. Glimcher emphasizes the need to make it easy for providers to integrate new technologies ethically, as they are motivated to provide the best care for their patients. In conclusion, the episode of "Self Funded" featuring Nick Glimcher sheds light on the intersection of entrepreneurship, healthcare challenges, and precision medicine innovations. Glimcher's entrepreneurial journey and insights highlight the importance of adaptability and consistent effort in achieving success. The challenges in the healthcare industry, particularly with insurance companies and payment issues, can be overcome through precision medicine and the integration of pharmacogenetic data. The efforts of companies like Blue Genes are aimed at improving clinical outcomes and mitigating the rising costs in healthcare. With bipartisan support and a focus on humanity and caring, the future of healthcare looks promising. Chapters: 00:01:22 Nick Glimcher's Journey of Adaptability and Opportunity 00:04:41 The Importance of Consistent Effort in Powerlifting 00:08:13 Insurance Payment Challenges in Healthcare 00:12:08 Pharmacogenetics: Personalized Medicine 00:18:00 Overcoming Limitations of Pharmacogenetic Testing 00:27:42 Genetic Makeup's Impact on Drug Effectiveness 00:32:07 Transforming Healthcare with Niche Data Analysis 00:46:02 Precision Medicine for Cost Mitigation in Healthcare --- Support this podcast: https://podcasters.spotify.com/pod/show/spencer-harlan-smith/support

Pharmacogenetics: Personalized Medicine for the Future In a this episode of the podcast "Self Funded" hosted by Spencer Smith, entrepreneur Nick Glimcher shared his journey from the world of commercial real estate to the healthcare industry. Glimcher's story highlights the importance of adaptability and seizing opportunities in different industries. He emphasizes the link between powerlifting and entrepreneurship, both requiring consistent effort and commitment for success. One of the key challenges in the healthcare industry, as discussed in the episode, is the complex landscape of insurance companies and payment issues. These challenges can be daunting and hinder the delivery of quality care. However, Glimcher believes that precision medicine holds the key to overcoming these challenges and revolutionizing healthcare. Precision medicine is an innovative approach that provides detailed and targeted care based on an individual's genetic makeup. Glimcher explains that precision medicine is the future of healthcare, with pharmacogenetics playing a crucial role in personalizing treatment plans. Pharmacogenetics is the science of determining which drugs work for an individual and which do not. While the science has been commercially viable since 2010, its widespread usage has been limited due to applicability issues. To address this issue, Glimcher's company, Blue Genes, has developed a software tool called The Blue Genes Solution. This tool aims to make pharmacogenetic data actionable in clinical settings. By integrating with pharmacy benefit managers (PBMs) and electronic medical records (EMRs), Blue Genes simplifies the interpretation of pharmacogenetic reports and provides instantaneous notifications to healthcare providers, ensuring that prescriptions are genetically efficacious. Cost mitigation in healthcare is a pressing issue that requires innovative solutions, such as precision medicine, and bipartisan support. Glimcher highlights the importance of government involvement in pushing for coverage determinations and legislation related to pharmacogenetics. He believes that there is bipartisan support for healthcare reform because humanity and caring are not political issues but fundamental aspects of being human. The episode also touches on the challenges faced by healthcare providers in adopting technology. Healthcare has been the last sector to embrace technological advancements, despite its critical role in keeping people alive and healthy. Glimcher emphasizes the need to make it easy for providers to integrate new technologies ethically, as they are motivated to provide the best care for their patients. In conclusion, the episode of "Self Funded" featuring Nick Glimcher sheds light on the intersection of entrepreneurship, healthcare challenges, and precision medicine innovations. Glimcher's entrepreneurial journey and insights highlight the importance of adaptability and consistent effort in achieving success. The challenges in the healthcare industry, particularly with insurance companies and payment issues, can be overcome through precision medicine and the integration of pharmacogenetic data. The efforts of companies like Blue Genes are aimed at improving clinical outcomes and mitigating the rising costs in healthcare. With bipartisan support and a focus on humanity and caring, the future of healthcare looks promising. Chapters: 00:01:22 Nick Glimcher's Journey of Adaptability and Opportunity 00:04:41 The Importance of Consistent Effort in Powerlifting 00:08:13 Insurance Payment Challenges in Healthcare 00:12:08 Pharmacogenetics: Personalized Medicine 00:18:00 Overcoming Limitations of Pharmacogenetic Testing 00:27:42 Genetic Makeup's Impact on Drug Effectiveness 00:32:07 Transforming Healthcare with Niche Data Analysis 00:46:02 Precision Medicine for Cost Mitigation in Healthcare --- Support this podcast: https://podcasters.spotify.com/pod/show/spencer-harlan-smith/support

Welcome to episode 036 of the podcast.  In this episode of 3-Minute Thursdays, 25th Histio Ambassador, Nate Milam talks about the power of pharmacogenetics and how you can take pain management into your own hands. Join us every week and escape for 3 short minutes into a place of hope and encouragement on your histio journey. Nate is the 25th Histio Ambassador and an HLH survivor.  Resources mentioned in the podcast: Invitae - https://www.invitae.com/en We'd love to hear your feedback!  Let us know if a 3-Minute Thursday touched you!  Reach out to podcast@histio.org and tell us your thoughts. Music: Walk Together by Olexy --- Support this podcast: https://podcasters.spotify.com/pod/show/histio/support

As you may have heard, we are launching a Patreon! For those that don't know what Patreon is, it's a platform that allows creators (like podcasters) to offer their followers more content, experiences, and even gifts. We have a survey that will be open for a limited time so get your input in now so we can provide the benefits you want. Maybe that's a one-on-one Zoom with me for mentorship or a genetics book/movie club or an appearance on the podcast! Let us know so we can make sure to offer it. Thanks for all your support for the podcast over the years. My guest today is Dr. Jamie Fettig, the Founder and CEO of TruGene Diagnostics. We are chatting about a breakthrough in eliminating variants of unknown significance - especially in relation to companion diagnostic tests and pharmacogenetics in oncology. Dr. Jamie Fettig is the Founder and CEO of TruGene Diagnostics, which is eliminating variants of unknown significance - especially in relation to companion diagnostic tests and pharmacogenetics in oncology. He graduated from Palmer University. Dr. Fettig previously worked in private practice and then transitioned into manufacturing and selling medical equipment. He also worked as a coach and trainer to fellow doctors. On This Episode We Discuss:Defining variants of unknown significance (VUS), pharmacogenetics and companion diagnosticsWhat TruGene Diagnostics doesThe GiggaAssayHow knowing if a breast cancer is HER2+ can help inform medications that people should be prescribedVUS in HER2 Tyrosine Kinase RegionWhat people should do if they get HER2+ cancer or their doctor wants to do a biopsy thinking it might be HER2+How cancer survival rates are impacted by utilizing precision medicine approaches with drugsHow TruGene Diagnostics' test differs from other PGx tests or Precision MedsHow pharmacogenomics can increase the efficacy of clinical trialsCheck out Dr. Fettig's papers:Heligenics: fulfilling the promise of the functional genome to enable precision medicine (March, 2023)Data Supporting a saturation mutagenesis assay for Tat-driven transcription with the GigaAssay (September 2022)GigaAssay – a high-throughput assay system for molecular functions and cell processes (July 2021)Check out DNA Today Episode 134 that Kira mentioned during this episode; it's with guest Dr. Kat Arney about cancer evolution. You can also stream other episodes about pharmacogenomics including Episode #108 with Becky Winslow, Episode #174 with Gregory Kellog, and last week's Episode #229 with Avni Santani! Stay tuned for the next new episode of DNA Today on April 7th, 2023, where we'll be discussing ChatGPT and AI In Genetics with Daniel Uribe of GenoBank! New episodes are released every Friday. In the meantime, you can binge over 225 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel. DNA Today is hosted and produced by Kira Dineen. Our social media lead is Corinne Merlino. Our video lead is Amanda Andreoli. Our Outreach Intern is Sanya Tinaikar. Our Social Media Intern is Kajal Patel. And our Graphic Designer Ashlyn Enokian.See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNAToday.com. Questions/inquiries can be sent to info@DNAtoday.com. Surely you have heard of whole genome sequencing, but what about rapid and ultra-rapid whole genome sequencing? This is an emerging method of diagnosing genetic conditions for quick management. PerkinElmer Genomics offers this incredibly valuable test, which can be life saving for ill babies and kids. Learn more in our full episode (#226) with PerkinElmer Genomics. You can visit perkinelmergenomics.com for more information. (Sponsored)Juno Diagnostics has developed the next generation of non-invasive prenatal tests so that all pregnant people can access a higher standard of care. Juno Diagnostics is the only genetic testing company on the market that performs NIPS for common aneuploidies on blood samples from a finger stick instead of a traditional venous blood draw. That means you collect your sample on your own time, at home, and still have NIPS at a CLIA laboratory! Juno's Hazel™ NIPS screens for common chromosome variations seen in pregnancy, such as Down syndrome or trisomy 21, trisomy 13, and trisomy 18 – in addition to testing for fetal sex. You can order this test yourself, or have your healthcare provider order for you. Head to JunoDx.com and use the code "DNATODAY” for 10% off! Keep your eye out for our full episode interview with experts from Juno Dx including fellow genetic counselor Katie Sagaser and Dr. Allison Rodgers. In the meantime, check out JunoDx.com to learn more about Hazel and their other test Birch (which tests just for the sex of your baby). (Sponsored)

Dr. Namandjé Bumpus, Ph.D. is U.S. Food and Drug Administration's (FDA) Chief Scientist ( https://www.fda.gov/about-fda/fda-organization/namandje-bumpus ). The Office of the Chief Scientist supports the research foundation, science, and innovation that underpins the FDA's regulatory mission. It does this through a broad framework that encompasses scientific collaborations, laboratory safety, the transfer of FDA inventions to the private sector, scientific integrity in FDA policy- and decision-making, the professional development of regulatory scientists, and its core research component—the FDA's National Center for Toxicological Research—which generates the vital data that the FDA requires for its regulatory decision-making and development of sound regulatory policy. Before joining the FDA, Dr. Bumpus was the E.K. Marshall and Thomas H. Maren Professor and chair of the Department of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine. She served previously as associate dean for basic research in the Johns Hopkins University School of Medicine. Dr. Bumpus' research has focused on drug metabolism, pharmacogenetics, bioanalytical chemistry, and infectious disease pharmacology. Dr. Bumpus joined the faculty at Johns Hopkins in 2010 as an assistant professor. She earned a bachelor's degree in biology at Occidental College in 2003, a doctorate in pharmacology at the University of Michigan in 2007 and completed a postdoctoral fellowship in molecular and experimental medicine at The Scripps Research Institute in La Jolla, CA in 2010. Dr. Bumpus currently serves as president-elect of the American Society for Pharmacology and Experimental Therapeutics. She previously served as chair of the NIH Xenobiotic and Nutrient Disposition and Action study section. Her many honors include the Leon I. Goldberg Award from the American Society for Clinical Pharmacology and Therapeutics, the James Gillette Award from the International Society for the Study of Xenobiotics, the John J. Abel Award in Pharmacology from the American Society for Pharmacology and Experimental Therapeutics and the Presidential Early Career Award for Scientists and Engineers, which is the highest honor bestowed by the United States government on early career scientists and engineers. Dr. Bumpus is an elected fellow of the American Association for the Advancement of Science. She became a Member of the National Academy of Medicine, Class of 2022, one of the highest honors in the fields of health, science and medicine. Support the show

I discuss pharmacogenomics (PGx) with Dr. Dave Kisor from Manchester University College of Pharmacy, which is located in Fort Wayne, IN. If you're interested in pharmacogenomics, you will like this episode! Bio (Feb 2023) Dave Kisor, PharmD is professor and director of pharmacogenomics at Manchester University. He graduated from The Ohio State University College of Pharmacy 1986 and completed a two-year fellowship in therapeutic drug monitoring/pharmacokinetics at OSU. Prior to joining Manchester, Dave was professor of pharmaceutical sciences at Ohio Northern University after being a research scientist at Burroughs Wellcome Co/GlaxoWellcome. He has been a clinical PGx consultant since 2012. He has over 80 peer reviewed publications including being the lead author on two pharmacogenomics textbooks. He is a past chair of the American Association of Colleges of Pharmacy (AACP) PGx SIG. Dave was named a Fellow of the American College of Clinical Pharmacology in 2017. In 2021 he received an AACP Innovations in PGx Teaching Award. His current research is related to PGx and opioid use disorder. He also serves as co-chair of the Pharmacogenomics Global Research Network (PGRN) Education Committee. Thank you for listening to episode 201 of The Pharmacist's Voice ® Podcast! To read the full show notes, visit https://www.thepharmacistsvoice.com.  Click on the podcast tab, and search for episode 201. Subscribe to or Follow The Pharmacist's Voice Podcast! Apple Podcasts Google Podcasts Spotify Amazon/Audible

Have you ever wondered why that pill you're taking for pain isn't really helping, or why it's causing side effects? Well, the “one size fits all” strategy for medicines is yielding to genetic profiling that predicts disease risk and drug response in a way that personalizes medicine. Mary Dugan-Jordan, an oncology nurse has suffered from […]

Have you ever wondered why that pill you're taking for pain isn't really helping, or why it's causing side effects? Well, the “one size fits all” strategy for medicines is yielding to genetic profiling that predicts disease risk and drug response in a way that personalizes medicine. Mary Dugan-Jordan, an oncology nurse has suffered from […]

Have you ever wondered why that pill you're taking for pain isn't really helping, or why it's causing side effects? Well, the “one size fits all” strategy for medicines is yielding to genetic profiling that predicts disease risk and drug response in a way that personalizes medicine. Mary Dugan-Jordan, an oncology nurse has suffered from […]

Have you ever wondered why that pill you're taking for pain isn't really helping, or why it's causing side effects? Well, the “one size fits all” strategy for medicines is yielding to genetic profiling that predicts disease risk and drug response in a way that personalizes medicine. Mary Dugan-Jordan, an oncology nurse has suffered from […]

In this episode, Dr. Jeffrey Strawn answers your most pressing questions from his presentation, Blue Genes: Using Pharmacogenetics to Guide Prescribing.

Pharmacogenetics testing: where are we today? Kristine Ashcraft, CEO, and founder of YouScript, a translational PGX start-up that Invitae recently acquired, joins us on the Beagle to discuss why it has been so hard to get the ball rolling on PGX testing. Kristine, who was called one of the 25 leading voices in precision medicine by BIS Medicine in 2019, lays out a roadmap to the integration of PGX testing into routine clinical care.

Join us this week for an exciting follow-up episode with Dr. Martin Dawes, GenXys' Chief Scientific Officer and Co-Founder, and Andrea Collins, a Clinical Pharmacist who leads Project Management at GenXys. This week, the tables are turned as they continue their engaging conversation from Part I about the behind-the-scenes work that goes into implementing pharmacogenetics into primary care.     Hosted by Dr. Martin Dawes, this podcast will provide insight into pharmacogenetics and its implementation into primary care with a focus on the pharmacy.    Show Notes: (1:09): Andrea Collins introduction (3:11): What is a pharmacogenetic (PGx) test? (6:36): Are PGx tests covered? (12:36): PGx and Clinical Decision Support Software (CDSS) (14:27): Medication reviews and PGx  (17:10): PGx through a pharmacist's view (18:59): How will data from a PGx test be used? (21:16): How do I choose a lab to do my test? (24:26): How are pharmacists a key role? (26:17): Closing remarks 

When fixing a problem, you cut it right at the source.   Jason A. Duprat, Entrepreneur, Healthcare Practitioner, and Host of the Healthcare Entrepreneur Academy podcast, talks about the potential of Functional Medicine and how it can help improve our current Healthcare system. In this episode, Jason shares his personal story about how the alarming state of Western Medicine has affected his family and how Functional Medicine could have been the key to preventing that outcome.   EPISODE HIGHLIGHTS Jason's sister recently passed away due to Stage 4 Colorectal Cancer. The US spends more on healthcare than any other country in the world, but among developed countries, is at the bottom in terms of health outcomes. Functional Medicine aims to find the root cause of a disease or illness and focuses on Health Optimization. Integrative Medicine is when a clinician uses Traditional forms of Medicine along with others (e.g. Acupuncture, Massage, and Chiropractic). Wikipedia articles are not credible sources as they can be edited by anyone. Examples of Functional Medicine are the following: Jason interviewed a Podcast Guest who specializes in "Pharmacogenetics," studying how a person's genes impact how they respond to medications. Genova Diagnostics uses the "GI Effects Comprehensive Stool Profile" wherein patients send in stool samples and test for various indicators of gut health. Toxins in mattresses due to flame-retardants turn into carcinogenic gaseous vapors, which is an example of what Functional Medicine looks out for. Functional Medicine is newer, evolving, backed by legitimate studies, and is a great opportunity for clinicians who want to do Medicine right.   3 KEY POINTS Functional Medicine is a newer approach that addresses the root cause of diseases. Western Medicine has much room for improvement. Functional Medicine will greatly improve our Healthcare System in several years.   TWEETABLE QUOTES “Mark my words: In the next several years, Functional Medicine is going to take hold and gain traction” .– Jason A. Duprat “Be the best clinicians and advocates you can be for your patients.” – Jason A. Duprat CONNECT WITH JASON DUPRAT LinkedIn | Facebook | Instagram | Youtube Email: support@jasonduprat.com   RESOURCES Want to become a Ketamine Therapy provider? Enroll NOW in The Ketamine Academy course: ketamineacademy.com/presentation Have a healthcare business question? Want to request a podcast topic? Text me at 407-972-0084 and I'll add you to my contacts. Occasionally, I'll share important announcements and answer your questions as well. I'm excited to connect with you! Do you enjoy our podcast? Leave a rating and review: https://lovethepodcast.com/hea Don't want to miss an episode? Subscribe and follow: https://followthepodcast.com/hea   #HealthcareEntrepreneurAcademy #healthcare #HealthcareBoss #entrepreneur #entrepreneurship #podcast #businessgrowth #teamgrowth #digitalbusiness

Remember Episode 67? https://www.youtube.com/watch?v=dVpl1UEBVXA (Like these and subscribe to our YouTube channel).   Monday  - Invitae Announcement https://ir.invitae.com/news-and-events/press-releases/press-release-details/2022/Invitae-Announces-Strategic-Business-Realignment-to-Accelerate-Its-Path-to-Positive-Cash-Flow-and-Realize-Full-Potential-of-Industry-Leading-Genetics-Testing-Platform/default.aspx  - Sign up for Ciitizen: https://syngap.fund/ciitizen  - CMO email: “While the announcement focused  primarily on our operations and product portfolio, I wanted to take this opportunity to reinforce that Invitae remains unwavering in its commitment to patients. Cultivating strong relationships with Patient Advocacy Groups remains central to our business and our patient-centric philosophy.   We will continue to collaborate closely with our Patient Advocacy partners and communities to educate patients and their families on the value of genetic testing in diagnosing and potentially preventing disease. Together with you, we remain steadfast in empowering and supporting patients and highlighting the many opportunities where genetic testing may be beneficial. “ Pharmacogenetics in case you are curious: https://ir.invitae.com/news-and-events/press-releases/press-release-details/2022/Invitae-Launches-Expanded-Pharmacogenomics-Panel-and-Specialized-Mental-Health-Panel/default.aspx     Tuesday  - Prosser Pre-Print - Mapping PTBP splicing in human brain identifies targets for therapeutic splice switching including SYNGAP1    - “We find that PTBP2 binding to SYNGAP1 mRNA promotes alternative splicing and non-sense mediated decay. Antisense oligonucleotides that disrupt PTBP binding sites on SYNGAP1 redirect splicing and increase gene and protein expression.”   - https://twitter.com/cureSYNGAP1/status/1549408144987652104?s=20&t=u5iAtpoucdyaiT06Vt77pg     Wednesday  - Sample collection at Stanford. - Planning for end of year, see below.   Thursday - CHOP Update  - https://www.helbiglab.io/   - https://www.youtube.com/watch?v=JVTnkQCtQNo    Friday - Disease concept interview, Rarebase & Colombia - WCMC is looking to add to the pile of disease concept studies, which we VERY MUCH need. For the pile see Vlaskamp 2019, Jimenez-Gomez 2019, Smith-Hicks 2021, Wright 2022, Lyons-Warren 2022. - https://www.rarebase.org/   - Vicky is also building community in LatAm, there is a reunion this weekend! https://twitter.com/VickyAArteaga/status/1544994120351059969?s=20&t=6f5x8BqfRFR5UyRvFMOc_w     FUNDRAISERS - MICE: Help us Make 2!  https://syngap.fund/2mice   - BIRTHDAYS: https://www.facebook.com/cureSYNGAP1/fundraisers     EVENTS - 7 Weeks: September 12-14 in San Diego https://globalgenes.org/event/rare-patient-advocacy-summit/   - 10 Weeks: October 8 in NJ - Caren Leib Gala https://www.syngapresearchfund.org/get-involved/fundraising/caren-leib-gala  - 10 Weeks: October 8 in SC - Scramble for SYNGAP https://www.syngapresearchfund.org/get-involved/fundraising/scramble-for-syngap   - 11 Weeks: October 12-15 in OH - Child Neurology Society  - 15 Weeks: November 12 in GA - Sparks of Hope Gala https://syngap.fund/soiree  - 16 Weeks: November 14-15 in MA - PMC summit titled Personalized Medicine & the Patient - 18 Weeks: December 1 & 2 in TN - Syngap Science Meeting - https://syngap.fund/treat    This is a podcast: subscribe to and rate this 10 minute #podcast #SYNGAP10 here https://www.syngapresearchfund.org/syngap10-podcast      Apple podcasts: https://podcasts.apple.com/us/podcast/syngap10-weekly-10-minute-updates-on-syngap1-video/id1560389818     Episode 68 of #Syngap10 - July 25, 2022    #Ciitizen #CareAboutRare #Syngap #epilepsy #autism #intellectualdisability #id #anxiety #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #GlobalCollaboration 

This week was ripe with a promising future! #s10e68 Remember Episode 67? https://www.youtube.com/watch?v=dVpl1UEBVXA (Like these and subscribe to our YouTube channel). Monday - Invitae Announcement https://ir.invitae.com/news-and-events/press-releases/press-release-details/2022/Invitae-Announces-Strategic-Business-Realignment-to-Accelerate-Its-Path-to-Positive-Cash-Flow-and-Realize-Full-Potential-of-Industry-Leading-Genetics-Testing-Platform/default.aspx - Sign up for Ciitizen: https://syngap.fund/ciitizen - CMO email: “While the announcement focused primarily on our operations and product portfolio, I wanted to take this opportunity to reinforce that Invitae remains unwavering in its commitment to patients. Cultivating strong relationships with Patient Advocacy Groups remains central to our business and our patient-centric philosophy. We will continue to collaborate closely with our Patient Advocacy partners and communities to educate patients and their families on the value of genetic testing in diagnosing and potentially preventing disease. Together with you, we remain steadfast in empowering and supporting patients and highlighting the many opportunities where genetic testing may be beneficial. “ Pharmacogenetics in case you are curious: https://ir.invitae.com/news-and-events/press-releases/press-release-details/2022/Invitae-Launches-Expanded-Pharmacogenomics-Panel-and-Specialized-Mental-Health-Panel/default.aspx Tuesday - Prosser Pre-Print - Mapping PTBP splicing in human brain identifies targets for therapeutic splice switching including SYNGAP1 - “We find that PTBP2 binding to SYNGAP1 mRNA promotes alternative splicing and non-sense mediated decay. Antisense oligonucleotides that disrupt PTBP binding sites on SYNGAP1 redirect splicing and increase gene and protein expression.” - https://twitter.com/cureSYNGAP1/status/1549408144987652104?s=20&t=u5iAtpoucdyaiT06Vt77pg Wednesday - Sample collection at Stanford. - Planning for end of year, see below. Thursday - CHOP Update - https://www.helbiglab.io/ - https://www.youtube.com/watch?v=JVTnkQCtQNo Friday - Disease concept interview, Rarebase & Colombia - WCMC is looking to add to the pile of disease concept studies, which we VERY MUCH need. For the pile see Vlaskamp 2019, Jimenez-Gomez 2019, Smith-Hicks 2021, Wright 2022, Lyons-Warren 2022. - https://www.rarebase.org/ - Vicky is also building community in LatAm, there is a reunion this weekend! https://twitter.com/VickyAArteaga/status/1544994120351059969?s=20&t=6f5x8BqfRFR5UyRvFMOc_w FUNDRAISERS - MICE: Help us Make 2! https://syngap.fund/2mice - BIRTHDAYS: https://www.facebook.com/cureSYNGAP1/fundraisers EVENTS - 7 Weeks: September 12-14 in San Diego https://globalgenes.org/event/rare-patient-advocacy-summit/ - 10 Weeks: October 8 in NJ - Caren Leib Gala https://www.syngapresearchfund.org/get-involved/fundraising/caren-leib-gala - 10 Weeks: October 8 in SC - Scramble for SYNGAP https://www.syngapresearchfund.org/get-involved/fundraising/scramble-for-syngap - 11 Weeks: October 12-15 in OH - Child Neurology Society - 15 Weeks: November 12 in GA - Sparks of Hope Gala https://syngap.fund/soiree - 16 Weeks: November 14-15 in MA - PMC summit titled Personalized Medicine & the Patient - 18 Weeks: December 1 & 2 in TN - Syngap Science Meeting - https://syngap.fund/treat This is a podcast: subscribe to and rate this 10 minute #podcast #SYNGAP10 here https://www.syngapresearchfund.org/syngap10-podcast Apple podcasts: https://podcasts.apple.com/us/podcast/syngap10-weekly-10-minute-updates-on-syngap1-video/id1560389818 Episode 68 of #Syngap10 - July 25, 2022 #Ciitizen #CareAboutRare #Syngap #epilepsy #autism #intellectualdisability #id #anxiety #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #GlobalCollaboration --- Send in a voice message: https://podcasters.spotify.com/pod/show/syngap10/message

In this week's podcast episode, Andrea Collins, a Clinical Pharmacist who leads Project Management at GenXys is joined by Dr. Martin Dawes, GenXys' Chief Scientific Officer, and Co-Founder. Listen as they engage in a lively conversation about the implementation of pharmacogenetics in primary care and the work that goes on behind the scenes to make it happen.   Hosted by Andrea Collins, this podcast will provide clear direction into how pharmacogenetics is implemented into primary care.  Show Notes: (0:35): Dr. Martin Dawes introduction (1:50): PGx in primary care (3:42): Gamechangers in PGx (6:25): Getting started with PGx (9:55): Why primary care? (14:59): Why is clinical decision support important for implementation? (19:55): Overcoming concerns over PGx testing (25:07): UK report on precision prescribing (29:20): Closing remarks

Can genomics find the perfect antidepressant for your body? [TW:MH,MI] This episode discusses mental health and mental illness. If you, or someone you know, needs support, call the BC Mental Health Support Line at 310-6789 or find Canada-wide resources right here. (Hyperlink: https://www.canada.ca/en/public-health/services/mental-health-services/mental-health-get-help.html) The world of pharmacology helps a lot of people manage mental health conditions such as depression, anxiety, bipolar disorder, and schizophrenia. But, frankly, it can often be a bumpy road to discover the right medication for your body. Dr. Kaylee Byers speaks with award-winning Genetic Counselor Dr. Jehannine Austin on how pharmaco-genomics is taking the guesswork out of prescriptions by observing your unique DNA blueprint. Spitting in tubes, traversing the ‘Dark Genome' and navigating mountains of optimistic (and not so optimistic) data may just hold the key to unlocking the enigmas of genomic science and psychiatry. With special appearances from Behavioral Neuroendocrinologist Dr. Travis Hodges and pharmaco-genomic testing partner Lisa Ridgway, we discuss the lived experiences and behavioral indicators of those living with complex mental health ailments. Listen to Nice Genes! wherever you get your podcasts, brought to you by Genome British Columbia. Resources:  What is Pharmacogenomics?: How it Works: What is Pharmacogenetics? Exploring Pharmacogenomics in our Mental Health: Pharmacogenomics for Depression Study Congratulations to Dr. Jehannine Austin, Recipient of $1.5M in Funding to Explore Pharmacogenomic Testing in Clinical Settings BC researchers are exploring the use of genomics to improve drug treatments for people with depression Pharmacogenomics Guided Prescription Changes Improved Medication Effectiveness in Patients With Mental Health-Related Disability: A Retrospective Cohort Analyses The genetics of depression: successful genome-wide association studies introduce new challenges Dr. Travis Hodges, exploring behaviour in rats: Patterns of Endocrine, Behavioural, and Neural Function Underlying Social Deficits after Social Instability Stress in Adolescent Rats  The Dark Genome: The Mysterious 98%: Scientists Look to Shine Light on Our Dark Genome A Dark Genome Link to Schizophrenia and Bipolar Disorder See omnystudio.com/listener for privacy information.

This is a Step 5 Episode*   In this episode, Tiffany, CEO of AiArthritis, is joined by Catherine Ames, from the Young Patients' Autoimmune Research & Empowerment Alliance, both persons living with AiArthritis diseases and both who attended the 16th Annual Personalized Medicine Conference in May 2022. Precision Medicine (PM) may currently be in the cancer space, but it's quickly moving into the autoimmune/autoinflammatory space and there are some things they want you to know. What is it? Why is it important to understand and what can you do to make sure you can benefit most from it as it enters our space?    They talk about its impact on prevention (yes, we said it), early detection, diagnosis, and even matching treatments based on genetic profiles and biomarkers (blood, tissues, for example). Also, PM may be a solution to capping the high cost of healthcare, which means it's as much of a research issue as a public policy issue.  *All main episodes that air on the 1st Sunday of each month are either Step 2 in our 6 step problem solving process (first time the topic is on the table) OR a Step 5, which is a revisit to the table. In a Step 5, we are ready to take action to solve a problem (create a resource, ask to join a project, etc.) Show Notes: Episode 74 – “EveryONE's Voice Precisely Matters”   00:52 – Tiffany welcomes listeners. 01:12 - Tiffany is a patient living with non-radiographic axial spondyloarthritis. 01:32 - Tiffany is joined by Catherine Ames, a college student living with Lupus. 04:10 - Catherine is here today to represent the Young Patients' Autoimmune Research & Empowerment Alliance which works to include patients age 16-23 in medical research. 08:00 - Catherine and Tiffany met at a conference on Personalized (Precision) Medicine. 08:28 - AiArthritis distinguishes between Personalized Medicine and Precision Medicine because Personalized Medicine is more about patient preference and Precision Medicine is based on biomarkers. 10:01 - The conference they attended was largely dedicated to treatment of cancer more so than treatment of autoimmune disease because cancer treatment really spawned the field of Precision Medicine based on genetic sequencing of excised tumors. 13:07 - AiArthritis and AREA are at the forefront of Precision Medicine research in the autoimmune arena because most experts don't anticipate serious breakthroughs in the immunology sphere with regard to Precision Medicine until 2025 or later. 15:05 - The keynote speaker of the conference talked about the importance of teaching the FDA and other regulatory agencies about innovative research. 17:08 - Early intervention with Precision Medicine could reduce the risk of comorbidities and increase the odds of achieving remission. 18:30 - Precision Medicine is intended to be expanded beyond cancer to other spheres within medical care, but there are access issues within the current healthcare system, especially in the United States. 19:23 - Precision Medicine has the potential to decrease healthcare costs in any system by intervening early to avoid patients developing complicated and expensive conditions. 23:20 - One example of Precision Medicine applications in AiArthritis is the use of biomarkers within RA to predict more aggressive forms of the disease. 24:10 - The reality is that AiArthritis diseases require expensive treatments that impose a significant cost burden on all healthcare systems, but only a minority of patients will respond to any specific treatment. 26:20 - The current practice of trial and error of drugs that have never even been tested in a clinical setting on a specific subgroup of autoimmune patients is wasteful and inefficient. 30:47 - AiArthritis encourages patients to get involved in clinical research by participating in the FORWARD National Databank or via other means. 31:27 - Visit AiArthritis.org/research for more information on how you can get involved in any of our research efforts. 33:33 - The concept of Precision Medicine sounds wonderful, but many patients are facing seemingly insurmountable barriers to access to care that may make them reluctant to participate in data collection efforts that might help move the field along. 38:16 - High costs of healthcare are driving access issues within all healthcare systems, so Precision Medicine should eventually - by way of reducing costs - increase access for all people. 45:18 - If patients could find treatments that better matched their specific conditions, they could improve their quality of life even if their disease is too advanced for remission to be possible. 46:00 - Tiffany and Catherine discuss pharmacogenetics. 49:43 - Pharmacogenetics has the potential to help match patients with the right pharmaceutical therapy based on their genome. 51:12 - Pharmacogenetics also has potential to anticipate drug-related toxicity before a patient develops an adverse reaction. 54:08 - Visit AiArthritis.org/research or aiarthritis.org/advocacy to get involved in promoting Precision Medicine. 55:01 - You can find Catherine @ChronicallyCatherine on social media or email her at chronicallycatherine@gmail.com.  55:35 - Find Young Patients' Area @yp_area on instagram or email them at youngpatientsarea@gmail.com. 56:29 - Tiffany thanks Catherine for her contributions to today's episode. 57:03 - Tiffany invites listeners to participate in any of the ensuing 360its following this episode. 58:12 - If you have something to say about today's episode, email us at podcast@aiarthritis.org or submit an anonymous comment at aiarthritis.org/rant. 58:56 - We are @IFAiArthritis on all social media platforms. 59:10 - Stay tuned for our brand new talk show website that will be premiering soon.   __________________________________________________________________ Patient Voices and All Other Stakeholders - Join our AiArthritis Voices Program and Connect to Opportunities to Have Your Voice Counted If you are a patient, a parent of a juvenile patient, or any other stakeholder (doctor, nurse, researcher, industry representative, or other health services person) - are you ready to join the conversation? It's your turn to pull up a seat. Join our new AiArthritis Voices program, where people living with AiArthritis diseases and other stakeholders who we need 'at the table' to solve problems that impact education, advocacy, and research sign up to have a voice in our initiatives. By signing up, you'll get notified of opportunities to be more involved with this show - including submitting post-episode comments and gaining insider information on future show topics. Patients and all other stakeholders are encouraged to join so we can match you with opportunities to pull up a seat and TOGETHER - as equals - solve the problems of today and tomorrow. JOIN TODAY! AiArthritis Voices 360 is produced by the International Foundation for Autoimmune and Autoinflammatory Arthritis. Visit us on the web at www.aiarthritis.org/talkshow. Find us on Twitter, Instagram, TikTok, or Facebook (@IFAiArthritis) or email us (podcast@aiarthritis.org).  Be sure to check out our top-rated show on Feedspot! 

Dr. Jamie Wilkey, Founder of PGx Consulting Confidence Academy and CEO of Arches Health is joined by our CMO, Dr. Bernard Esquivel, to share her thoughts on implementing pharmacogenetics into point of care and the changing role of pharmacists.    Show Notes:  (0:15) - Dr. Jamie Wilkey introduction  (3:08) - PGx as a piece of the puzzle (5:16) - Delivering PGx to point of care (9:20) - Education and training  (12:02) - The role of the pharmacist  (15:49) - Trends for pharmacists (17:52) - Takeaways for pharmacists (20:53) - Closing remarks 

Welcome to the Head to Heal Podcast Heads up! I am not a medical doctor and you should always seek help from a physician before beginning any new health regime. On this weeks Episode Jiordana talks all about her3 toping 5 tips on reduce hunger / cravings -- and guess what, they are TOTALLY FREE! We cover: - Water - Sunlight - Delaying hunger - Dopamine/ Creativity - Nervous system Safety Hit the LIKE & SUBSCRIBE button! This keeps the information free and available to everyone. Don't forget to share this episode with someone who you feel can value from it! Links: Book a free consultation! “Daily Dose” Mind-Full Microdosing Course Apply for 1:1 coaching Website: www.themindfullclinic.com Instagram: @themindfullclinic Email: jiordana@themindfullclinic.com References: Blum K, Braverman ER, Wood RC, Gill J, Li C, Chen TJ, Taub M, Montgomery AR, Sheridan PJ, Cull JG. Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics. 1996 Aug;6(4):297-305. doi: 10.1097/00008571-199608000-00003. PMID: 8873216.

Imagine for a second if you could have treatment which fits you better than a tailored suit. In some cases, biostatistics tools and custom medicines like gene therapy open new doors for patients. After today's pod, you'll know all the practical and impractical uses of precision medicine for patients.So what is precision medicine? Aren't doctors already supposed to customize treatments for each given patient's situation? The short answer is yes but the longer answer leaves a key gap I want to talk about. What the majority of doctors follow is evidence-based medicine. This is a time-tested process—a patient arrives to the clinic with XYZ history and suffers from XYZ complications. The provider then suggests the best clinical or surgical options based on what has worked for the disease in the past as well as what makes sense from experience in med school, residency, etc. In essence, treatment is targeted for alleviating symptoms or root causes of symptoms, which is great. Notice that potential solutions are personalized to the given disease more so than the patient directly. That distinct intent is where precision medicine begins. As you may imagine, patients with a given disorder can have wildly different reactions to similar treatment. To be clear, evidence-based medicine has way more benefits than drawbacks—precision medicine has been promoted over the last couple decades as taking care to another level. The greatest benefit patients get from precision medicine is that any treatment you take is created from your specific environment, lifestyle, and genetic makeup. For example, if someone ends up with a disease like lung cancer, there could be a customized therapy targeting the problem with that patient's genome in mind.Although genomics is a huge part of precision medicine today, especially with everything we've learned since the US's Human Genome Project finished up in the 2000s, precision medicine was in motion before then when the textbook Pharmacogenetics was published in 1962 by Dr. Werner Kalow. A helpful article on the Harvard Data Science Review dives more into the historical buildup of precision medicine, which I'll link on my Substack page at rushinagalla.substack.com. Even before the 20th century, doctors were interpreting data linked to the onset and treatment of disease to craft better options. For example, there might be a group of patients who all suffer from severe asthma. Precision medicine could in theory still occur here without going into each patient's genetic profile. In this situation, doctors could see that patients one to 100 live in cleaner-air environments than patients 101 to 150. Maybe patients 80 to 120 have other issues that make the asthma worse or better, and so on. Modelers then crunch and reformat all that unstructured data to suggest treatment for each individual. Obviously, evidence-based medicine isn't going away. If a whole region is dealing with an unusual flu outbreak, we know that making tweaks to the annual flu vaccines will do a reasonable job targeting the specific changes made by that strain of the flu itself without needing to consider every individual's situation case by case. Evidence-based care is still part of the foundation of what precision medicine does. But since in this day and age we're generating so much data and have a better understanding of our genetic code, there is more runway for precision medicine to take off such that patients may someday get one-of-one solutions to their issues.Shifting over to the genetic focus of modern precision medicine shows us that we can deal with patients who respond differently to common treatments. Some patients may need varying dosages, treatment lengths, or alternative choices because of side effects. Having 100% unique solutions for each person's medical issue is wonderful and utopian on paper. The reality of precision medicine's main playing field is cancer treatment, which is life-saving but not cheap. ~90% of precision treatments approved by the FDA in 2018 were for cancer indications. Well-known cancer therapy brand labels like Keytruda by Merck or Herceptin by Roche cost multiple hundreds of thousands a year before insurance discounts. There also could be issues between how customized the medicine is versus whether the patient actually matches up well to do the treatment. Cancer therapies are anything but short experiences—not all patients can handle extended courses even if the treatment is a perfect match for their genes. Not to mention that a skilled oncologist wouldn't be enough to oversee the treatment since there would be considerable expense involved for doing genetic sequencing and reading out results that not all doctors are trained to understand. Not all medical facilities are equipped to perform this kind of care regardless of superb personnel. It's also difficult to do a clinical trial to make better custom medicines in the first place since, by definition, uncommon diseases affect less people so clinical study recruitment becomes a separate challenge. This is part of why the biggest irony of precision medicine is that individual solutions improve only when you accumulate enough data at the population level. There is nothing inherently wrong there, but that's just where precision medicine is at for now.A recent in-depth review by the Brookings Institution think tank offers some insight on how “agile governance,” which is a policy approach for regulators to make better private and public partnership decisions for the purposes of innovation, can bring down precision medicine costs and ease logistical problems. That analysis focuses on aggregating private and public health care data, improving direct to consumer genetic testing incentives, and building international relationships between drug regulators among other possible initiatives to make precision medicine practical.Without a doubt, the medical field is still a number of years away from having consistent treatments with a capacity for individual genetic modifications serving patients at the outpatient clinic level. However, your care can still improve with better decision-making that still takes your social, genetic, and medical history into account so medicine doesn't reduce itself to just a bunch of if-then statements. Another field of medicine that shouldn't be reduced to algorithms is mental health, which is the prime subject of next week's pod. At that time, we'll learn about what mental health resources exist and how to use them well. Stay tuned and subscribe to Friendly Neighborhood Patient for the big and small pictures of healthcare. I'll catch you at the next episode. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit rushinagalla.substack.com

PRECISION MEDICINE IN MENTAL HEALTH How far have we come in? Discussing pharmacogenetics and how it helps determine individual treatments with Behnaz Sarrami on this episode of The Cure with Aimee Cabo. Behnaz Sarrami, MS, Doctor of pharmacy is a pharmacogenomics medical science liaison and a host to Pgx for pharmacist podcast, which is one of the top 20 genomics podcasts globally. https://www.missouripgx.com/ Today's show features spiritual poems based on popular songs. Aimee Cabo is the host of syndicated live radio show The Cure, an inspirational speaker, a nurse, and a Christian award winning author. Latest book available now - Inspired by the Holy Ghost, Godisthecure.com

PRECISION MEDICINE IN MENTAL HEALTH How far have we come in? Discussing pharmacogenetics and how it helps determine individual treatments with Behnaz Sarrami on this episode of The Cure with Aimee Cabo. Behnaz Sarrami, MS, Doctor of pharmacy is a pharmacogenomics medical science liaison and a host to Pgx for pharmacist podcast, which is one of the top 20 genomics podcasts globally. https://www.missouripgx.com/ Today's show features spiritual poems based on popular songs. Aimee Cabo is the host of syndicated live radio show The Cure, an inspirational speaker, a nurse, and a Christian award winning author. Latest book available now - Inspired by the Holy Ghost, Godisthecure.com

Pharmacokinetics- pharmacodynamics, pharmacogenetics with a nursing twist.

JAACAP January 2022: Contributing Editor Dr. Desiree Shapiro interviews Drs. Jennifer L. Vande Voort and Paul E. Croarkin on evaluating the clinical impact of combinatorial pharmacogenetics testing in a double-blind, randomized, controlled effectiveness study for the pharmacologic treatment of adolescents with depression.

JAACAP January 2022: Contributing Editor Dr. Desiree Shapiro interviews Drs. Jennifer L. Vande Voort and Paul E. Croarkin on evaluating the clinical impact of combinatorial pharmacogenetics testing in a double-blind, randomized, controlled effectiveness study for the pharmacologic treatment of adolescents with depression.

How  can we use genetics to increase our health and longevity? Find out as we speak with Islam Mansour, Co-Founder and CEO of MyGenomd.com. He has a Bachelors in Bioinformatics from the Technical University of Munich.Take away points: -Pharmacogenetics has potential to identify gene-drug interactions which can affect the metabolism and bioavailability a drug.-Mental health is an under appreciated area for genetic risk factor identification although the challenges are significant-Privacy and regulatory issues remain a significant hurdle for companies seeking to develop products and services in the genomics splace-The mygenomd.com service is currently available in beta at no charge for those interested in exploring their own genetic risk profile.https://mygenomd.com/ https://www.headspace.com/  #longevity #wellness  #Ketones #lifestylemedicine #younger #ketosis #biohacking #acetone #RobertLufkinMD #mansour #genetics *** CONNECT WITH ROBERT LUFKIN MD ON SOCIAL MEDIA ***Web: https://robertlufkinmd.com/ Twitter:https://twitter.com/robertlufkinmdYoutube: https://www.youtube.com/RobertLufkinMD*** GOT A SUGGESTION FOR A SHOW? ***Contact us at: https://robertlufkinmd.com/contact *** SPONSORSHIPS & BRANDS ***We do work with sponsors and brands. If you are interested in working with us for your health industry product or service, please contact us at: https://robertlufkinmd.com/contact  NOTE: This is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have. Never disregard professional medical advice or delay in seeking it because of something you have seen here. Robert Lufkin MD may at any time and at its sole discretion change or replace the information available on this channel. To the extent permitted by mandatory law, Robert Lufkin MD shall not be liable for any direct, incidental, consequential, indirect or punitive damages arising out of access to or use of any content available on this channel, including viruses, regardless of the accuracy or completeness of any such content.Disclaimer: We are ambassadors or affiliates for many of the brands we reference on the channel.Support the show (https://robert-lufkin.mykajabi.com/membership)

In the final episode of this season,  past RCPA President Dr Michael Dray speaks with Prof Graeme Suthers. Prof Suthers is the National Director for Sonic Genetics and is one of Australia's most respected experts in the field of genetics.  This episode delves into the world of pharmacogenetics and its demonstrated clear benefits. Pharmacogenetics is standard practice in many other countries, it is still underrepresented in Australia and New Zealand.Copyright © 2021 The Royal College of Pathologists of Australasia. All rights reserved.

With clinical genetics still being a nascent field today, a lot of effort needs to be made by many healthcare practitioners to update their knowledge of the field. In this episode, Fadhli and Esther revisited some fundamental concepts in genetics, particularly its relation to drug action in the body. Basic terms such as pharmacogenetics, pharmacokinetics and pharmacodynamics were explained in this episode and we also touched briefly about nutrigenetics and its recent development. Learn more about us: www.nalagenetics.com

Neda Leonard, CEO of Rx Gene IQ and a Dual Board-Certified Pharmacist in Pharmacotherapy and Geriatrics, joins us today, with her patient, Joey Stanford, to discuss how precision medicine identified the underlying cause of Joey's lifelong health issues. Show Notes: (00:35) – Introducing Neda (01:30) – Neda Leonard's background and professional interests (07:00) – Introducing Joey Stanford (07:50) – Joey's Story (12:30) – The Complications of Multiple Insurers (15:00) – Joey's two big discoveries from Pharmacogenetics (18:50) – Say Goodbye to Trial and Error (19:30) – How to solve the patient's puzzle (24:00) – How to decongest the “Polypharmacy Highway” (25:00) – Education and Advocacy to Scale (26:40) – What is the problem and why are there so few solutions for it? (31:40) – Using a team effort to detect which patients benefit the most (35:00) – Closing remarks

Implementing Pharmacogenetics in your Consulting Practice

Welcome to another episode of Pediatric Meltdown. My guest for today is Dr. Lisa Namerow, a Board-certified psychiatrist triple-boarded in pediatrics, child psychiatry, and general psychiatry. She has been in the pediatric healthcare space for almost 30 years, directing the consultation services to in-patient pediatrics, and the access to mental health programs for pediatricians.  Her areas of research have been pharmacogenetics, and the impact of clinical pathways and standardized care for eating disorders, somatic symptoms, and related disorders, and delirium, and serves on the American Academy of Child and Adolescent Psychiatry Committee on the physically ill child. [00:01] Dr. Lisa Namerow Shares Her Story With Us  Dr. Namerow shares how she became a child and adolescent psychiatrist  She introduces the field of Pharmacogenomics Pharmacogenomics vs. Pharmacogenetics  [06:12] Genetics 101  Myths about Pharmacogenomics Pharmacodynamic Genes and Pharmacokinetic Genes What we need to know Dr. Namerow's analogy for genes  The relationship between medicines and gene findings  [16:19] Deciding if Gene Testing Can Be Helpful What oncologists should know about prescribing medicines How a pediatrician can utilize genetic testing  The screening questions to help pediatricians decide on genetic testing [26:37] Genetic Testing in ADHD, Depression, and Anxiety Talking with parents about genetic testing How the serotonin transporter works in the body  Genetics in the context of ADHD, depression, and anxiety  [36:10] The Best References for Primary Care  Dr. Namerow's interesting insights about primary care Her message for clinicians that you should not miss  Dr. Namerow's message for her younger self   [46:10] Closing Segment   Our advice for all working moms out there Final takeaways: The role of certain relevant genes in drug response The industry's detailing can be misleading There are some very relevant gene medication pairs An analogy about Gentamicin you should not miss Using Venlafaxine  Facts about Cytochrome P450 Screening questions to decide if genetic testing can be helpful Select medications based on evidence and guidelines Key Quotes: “What is true is that genes do code for both the enzymes that metabolize medicines, and they also code for the proteins that are the site of the action of medication.” - Dr. Lisa Namerow “[It's] heartbreaking that we don't have a system that cares for these kids in the way that they should be cared for, and that it falls on primary care.” - Dr. Lisa Namerow Email lnamerow@connecticutchildrens.org to connect with Dr. Namerow or check out https://www.connecticutchildrens.org (Connecticut Children's Medical Center) to know more about her work.  Resources Mentioned: https://bit.ly/3jIxpQf (Pharmacogenomics: An Update for Child and Adolescent Psychiatry) https://www.nncpap.org/map (Child Psychiatry Access Programs by state) https://ki.se/en (Karolinska Institutet) https://www.cincinnatichildrens.org/bio/S/jeffrey-strawn (Dr. Jeffrey R. Strawn) If you'd like to connect with me, you can find me on https://www.linkedin.com/in/dr-lia-gaggino-80322a31/ (LinkedIn), https://www.facebook.com/DrLiaGaggino/ (Facebook), and https://twitter.com/gagginol?lang=en (Twitter) or email me at gagginol@yahoo.com. To learn more about me visit https://www.medicalbhs.com/ (https://www.medicalbhs.com/) LOVE WHAT YOU HEARD? Leave us a 5-star review so we can continue to provide you with great content. Share this episode and help people know more about children's health and well-being.

Dr. Pastore shares the science and latest research behind coronavirus, how it differs from COVID-19 and what makes it so dangerous. As he is actively treating those with the virus, he covers the lesser-known symptoms, the genetic polymorphisms (gene errors) that put some more at risk than others beyond age and pre-existing medical conditions, the current status of treatment for COVID-19 and what you can do to keep you and those around you safe.   SHOW NOTES Review of Dr. Pastore's qualifications [0:20] PhD Biomedical informatics, nanomedicine and clinical informatics from Rutgers University, School of Health Professions Expertise is understanding biomedical sciences, human genetics & RNA mechanisms, disease processes & systems, nanomedicine, drug discovery Graduate degree in Human Nutrition, Certified Nutrition Specialist    All of the information today is backed by science [3:00]   What is the Coronavirus and what is COVID-19 and how does this compare to SARS [3:45] Coronavirus - simply type of virus, under microscope has pointed structure looks like it wears a crown  Been exposed to coronavirus for a long time - cold, mild upper respiratory tract infection where bodies fight back - no cure  200+ different types “Novel” coronavirus = newly identified coronavirus type, no resistance against it  SARS 2003-2004 [6:20] Severe acute respiratory syndrome, caused by a novel coronavirus at the time Jumped from animal kingdom to humans, which is what is believed to have happened with the new 2019 coronavirus  COVID-19 [7:05] The upper respiratory infection some people develop after contracting the novel 2019 coronavirus (hence the name COVID-19)   You can be exposed to the coronavirus, be a carrier of the coronavirus, potentially exhibiting zero symptoms ever, transmit the virus to someone else and they can develop COVID-19 symptoms [7:30]   Coronavirus is spreading faster than SARS in 2003 [8:00] Less severe of an illness in the majority of those infected when compared to SARS Those with strong immune systems may only ever feel incredibly mild cold/flu symptoms or nothing at all, yet are giving the coronavirus to others with weaker immune systems [9:40] There are some individuals who do not feel sick, infect others, and then  develop COVID-19 symptoms    What makes the coronavirus so dangerous? [10:50] Spreading faster than any other virus in history  Those that have passed away from COVID-19 experienced a “cytokine storm” [11:30] Mutli-factorial hyper-inflammatory process  Over-stimulates the immune system factors, causing the lungs to shut down the normal process of breathing  Genetic polymorphism (genetic expression) in gene ACE2 can allow COVID-19 to get deeper into the lungs, greater chance of developing cytokine storm requiring hospitalization & ventilation [13:25] As of April 9, 2020, 25% of people walk around asymptomatic (constantly changing) [17:00] was 17.3% March 20th, 2020 People need to behave like they have the infection   Less-known/more rare symptoms of the coronavirus beyond cough/fever/chills [18:00] 3% of carriers present with pink-eye, can be the only symptom Diarrhea & other gastrointestinal/digestive complaints can be your only symptoms, don't assume it's a stomach bug or bad food  Loss of taste or smell  Sudden confusion - potentially caused by reduced blood-oxygen levels   What causes the more common symptoms [22:05] Dry “barking” cough, fever, chills, body aches, headache, shortness of breath, congestion  Virus interacting with immune system  Virus is replicating within body [22:45] Virus is RNA strands that fool your own cells into reproducing the virus (making your body “photocopy” the virus to take over more of your body) and then bust out of cells & take over nearby healthy cells   Replication of virus + immune system response causes the common symptoms    Immediately notify your physician if these symptoms arise, get immediate medical help if you have trouble breathing or pale/bluish skin [24:30] How long does it take to show symptoms? [25:15] 2-14 days from time of exposure, if at all Some reports of people being sick/developing symptoms beyond that  Learning more about how long virus can survive.  can live 3 days on stainless steel, 24 hours on package delivered to your door [26:25]   Who's most at risk? [27:00] Those with pre-existing conditions like diabetes, heart disease, lung diseases Immuno-compromised individuals - HIV, autoimmune diseases, undiagnosed or newly diagnosed celiac disease patients that are sIgA deficient    Recovery [29:15] Some feel fine after 3 days, some passing away - why? Genetic ACE2 polymorphism Some have the ACE2 polymorphism that better prevents the coronavirus from infecting the body  Pre-existing conditions, those with poor health  Body produces surfactant chemical that makes lungs sponge-like [31:05]  Genetic polymorphism that lowers surfactant production, makes lungs less sponge-like and makes breathing more challenging with COVID-19     What can we do? [32:15] Pretend you have the coronavirus  Social distancing - use technology to virtually connect with others REALLY wash your hands - scrub & sing “Happy Birthday” twice Hand sanitizer - minimum 60% alcohol  Other types are NOT designed to kill novel/new viruses  Stay home as much as possible - 6 feet from others is not enough  Wear a mask when going out To protect others from you Don't touch your face before washing your hands Study showed even trained, educated medical professionals touch their face 23 times per hour Clean & disinfect all surfaces that could have been exposed (groceries, counter where you rested groceries, car surfaces)  Alcohol-based surface cleaners need to have at least 70% alcohol  Strip off & wash your clothing in hot water, warm shower with soap as soon possible So far, we know virus can live on cloth for 3 days  How is COVID-19 treated? Current research shows…. [45:00] No FDA/CDC/WHO approved medical treatment Hospitals are practicing palliative care, symptom treatment  Ongoing experimental medical trials around the world (approx. 60 so far) NYU hyperbaric oxygen therapy - putting COVID-19 patients in more oxygen-rich environment, previously used to treat lung damage  Repurposing FDA-approved drugs to treat COVID-19 [47:15] Scientists are using drugs that have already been approved for other conditions and are currently being studied on effect to combat COVID-19 & slowing the spread within the body  Limits the virus spread so your own immune system can battle it  DRUG TRIAL: Remdesivir Believed to inhibit the action of RNA polymerase, intravenous delivery Targets how coronavirus replicates DRUG TRIAL: Galidesivir Viral RNA-polymerase binder, intravenous delivery DRUG TRIAL: Camostat Transmembrane protease, serine 2 inhibitor Blocks penetration of coronavirus to get into cell  DRUG TRIAL: Favipiravir  Selective viral RNA-polymerase inhibitor, delivered orally Two HIV drugs being studied right now DRUG TRIAL: Darunavir and Cobicistat, delivered orally DRUG TRIAL: Fingolimod  Sphingosine 1-phosphate receptor modulator, delivered orally Class of drugs used as immunomodulators and are used in conditions such as multiple sclerosis. Calms the immune system/cytokine storm to prevent it from attacking your own cells DRUG TRIAL: Plaquenil, better known as hydroxychloroquine  May inhibit the terminal glycosylation of ACE2 of this virus   These drugs SHOULD NOT be taken as a prophylactic / to “prevent” the coronavirus [51:00] All medications have side effects Pharmacogenetics - study of genetic reaction to drugs  (99.999% accurate) Based on an individual's genetics and polymorphisms, some may have opposite reaction and worsen health Can not respond to a drug Won't be one specific drug to treat it Instead, a polypharmacy - multiple options to treat based on genetics and other pre-existing medical conditions  Testing accuracy & false negatives [57:25] NIH estimates weeks away from a finger-prick test with almost 100% coronavirus diagnosis accuracy  Current testing of throat swabs 87.3% accurate, at best 13 of every 100 people that have been tested are given a false negative and are out in public infecting others    Vaccination? [60:00] Over a year out, but trials are underway Using plasma of those that have recovered from the virus Cell-surface receptor to suppress cytokine storm (keep immune system calm to prevent degrading of lung function)  When vaccine is available, celiacs should get tested to ensure vaccine is effective (often times they do not)   The future evolution of the coronavirus [63:20] Hard to determine next 6 months, constantly changing Hoping to flatten curve - signs are showing improvement Less infected, more time to react  The faster everyone does their part, the faster the curve will flatten Drug trials to conclude in a few months - more answers to what drugs work for certain categories of people   Conclusion [66:30] Do your part - stay home www.drrrobertpastore.com @drrobertpastore LINKS: EPA Disinfectants for Use Against SARS-CoV-2 https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2   CDC Cleaning and Disinfection for Households https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cleaning-disinfection.html

This is it folks! The last episode-our 2018 wrap up show! Tune in to hear Megan Vallis and I review the top developments of the year. Meghan is the Senior VP of Consulting at Apri Insurance Services Inc. As one of the industry's brightest stars, it was amazing to hear her thoughts on these topics. We cover everything from National Pharmacare, Pharmacogenetics, Virtual Care, HSA's and even give you a warning that the Robots are coming! Finally, Meghan lays out her predictions for 2019. It's been a great year for the podcast. I hope you have enjoyed it! RB

This is it folks! The last episode-our 2018 wrap up show! Tune in to hear Megan Vallis and I review the top developments of the year. Meghan is the Senior VP of Consulting at Apri Insurance Services Inc. As one of the industry's brightest stars, it was amazing to hear her thoughts on these topics. We cover everything from National Pharmacare, Pharmacogenetics, Virtual Care, HSA's and even give you a warning that the Robots are coming! Finally, Meghan lays out her predictions for 2019. It's been a great year for the podcast. I hope you have enjoyed it! RB